Peripheral T-Cell Lymphoma, Not Otherwise Specified: Diagnosis and Therapeutic Approaches for the Advanced Practice Provider

Overview

Journal J Adv Pract Oncol

Date 2024 Nov 20

PMID 39563965

Authors

Karla V Ow

Ann Vo

Jonathan Cunningham

Affiliations

Soon will be listed here.

Abstract

T-cell lymphomas (TCLs) have a unique pathobiology, clinically aggressive course, and poor prognosis. Recently, there have been significant advances in understanding the molecular genetic alterations of TCLs through next-generation sequencing. This has led to the development of specific therapeutic molecules. This review aims to provide an up-to-date overview of the current therapeutic approaches for the subtype peripheral T-cell lymphoma, not otherwise specified.

References

Al-Zahrani M, Savage K . Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Review of Current Disease Understanding and Therapeutic Approaches. Hematol Oncol Clin North Am. 2017; 31(2):189-207. DOI: 10.1016/j.hoc.2016.11.009. View

OConnor O, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B . Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29(9):1182-9. PMC: 3083873. DOI: 10.1200/JCO.2010.29.9024. View

Coiffier B, Pro B, Prince H, Foss F, Sokol L, Greenwood M . Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012; 30(6):631-6. DOI: 10.1200/JCO.2011.37.4223. View

Broccoli A, Zinzani P . Peripheral T-cell lymphoma, not otherwise specified. Blood. 2017; 129(9):1103-1112. DOI: 10.1182/blood-2016-08-692566. View

Zhang J, Briski R, Devata S, Kaminski M, Phillips T, Mayer T . Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL). Am J Hematol. 2017; 93(3):394-400. PMC: 5803354. DOI: 10.1002/ajh.24992. View

Siaghani P, Wong J, Chan J, Weisenburger D, Song J . Epidemiology and Pathology of T- and NK-Cell Lymphomas. Cancer Treat Res. 2019; 176:1-29. DOI: 10.1007/978-3-319-99716-2_1. View

Oluwasanjo A, Kartan S, Johnson W, Alpdogan O, Gru A, Mishra A . Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS). Cancer Treat Res. 2019; 176:83-98. DOI: 10.1007/978-3-319-99716-2_4. View

Swerdlow S, Campo E, Pileri S, Lee Harris N, Stein H, Siebert R . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90. PMC: 4874220. DOI: 10.1182/blood-2016-01-643569. View

Horwitz S, OConnor O, Pro B, Illidge T, Fanale M, Advani R . Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2018; 393(10168):229-240. PMC: 6436818. DOI: 10.1016/S0140-6736(18)32984-2. View

10.

Horwitz S, Ansell S, Ai W, Barnes J, Barta S, Brammer J . T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(3):285-308. DOI: 10.6004/jnccn.2022.0015. View

11.

Horwitz S, OConnor O, Pro B, Trumper L, Iyer S, Advani R . The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2021; 33(3):288-298. PMC: 9447792. DOI: 10.1016/j.annonc.2021.12.002. View

12.

OConnor O, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J . Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol. 2015; 33(23):2492-9. PMC: 5087312. DOI: 10.1200/JCO.2014.59.2782. View

13.

Wudhikarn K, Bennani N . How to Sequence Therapies in Peripheral T Cell Lymphoma. Curr Treat Options Oncol. 2021; 22(9):74. DOI: 10.1007/s11864-021-00873-w. View

14.

Toner K, Bollard C, Dave H . T-cell therapies for T-cell lymphoma. Cytotherapy. 2019; 21(9):935-942. DOI: 10.1016/j.jcyt.2019.04.058. View

15.

Zain J, Hanona P . Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management. Am J Hematol. 2021; 96(8):1027-1046. DOI: 10.1002/ajh.26270. View

16.

de Leval L, Jaffe E . Lymphoma Classification. Cancer J. 2020; 26(3):176-185. DOI: 10.1097/PPO.0000000000000451. View

17.

Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T . Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30(18):2190-6. DOI: 10.1200/JCO.2011.38.0402. View

18.

Hathuc V, Kreisel F . Genetic Landscape of Peripheral T-Cell Lymphoma. Life (Basel). 2022; 12(3). PMC: 8954173. DOI: 10.3390/life12030410. View

19.

Mercadante S, Aielli F, Adile C, Ferrera P, Valle A, Fusco F . Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients. Support Care Cancer. 2015; 23(11):3249-55. DOI: 10.1007/s00520-015-2720-y. View

20.

Coiffier B, Pro B, Prince H, Foss F, Sokol L, Greenwood M . Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014; 7:11. PMC: 4016573. DOI: 10.1186/1756-8722-7-11. View